IP Library Granted Patent US 7,744,907
Granted Patent B2
US 7,744,907 · App. 11/881,598 · Granted Jun 29, 2010

Ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in the method

Assignee: Stichting Dienst Landbouwkundig Onderzoek
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,744,907
App. No.
11/881,598
Granted
Jun 29, 2010
Kind
B2
Abstract

The invention relates to an ex vivo animal or challenge model as a method to identify protective (recombinant) proteins and rapidly measure protective immunity in intestinal segments directed against parasites and vaccines directed against parasitic infections. The invention further relates to vaccines directed against infection with parasites, such as Fasciola hepatica , which vaccines contain protective (recombinant) proteins identified and shown to be protective in studies using the ex vivo model. The invention further relates to protective (recombinant) proteins obtained from newly excysted juveniles (NEJ) of Fasciola hepatica . The protective (recombinant) protein corresponding to an NEJ protein has an apparent molecular weight of 32 kD and an N-terminal amino acid sequence comprising the sequence XXDVSWPFWDRMYNY (SEQ ID NO:1).

Claims (9)

1. An isolated or recombinant protective protein derived from a proregion of a cathepsin-like protease that is specific for a newly excysted juvenile (NEJ) stage of Fasciola hepatica wherein the protein comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:24, and SEQ ID NO:26.

2. The isolated or recombinant protective protein according to claim 1 , as shown to be protective in a method comprising using an ex vivo animal or challenge model to measure protective immunity directed against a parasite.

3. The protective protein of claim 1 , wherein said protein is a recombinant protein.

4. A vaccine comprising the protective protein of claim 1 .

5. The vaccine of claim 4 further comprising a pharmaceutically acceptable vehicle.

6. The vaccine composition of claim 5 , wherein said protective protein is recombinant.

7. A diagnostic test comprising: the protective protein of claim 1 and a molecule to detect immune complexes between the protective protein of claim 1 and antibodies from a sample of a subject to be tested.

8. A method for immunizing an animal against infection by Fasciola hepatica , the method comprising administering to the animal the vaccine composition of claim 5 .

9. The method according to claim 8 , wherein Fasciola hepatica is of the type that infects a host through a mucosal or skin surface.

Assignments (2)
CHANGE OF NAME Recorded Oct 6, 2016
From: STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK
To: STICHTING WAGENINGEN RESEARCH
Reel/Frame 039959/0338 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2007
From: VAN MILLIGEN, FLORINE J.; CORNELISSEN, JOHANNES BERNARDUS WILHELMUS JOSEPH; BOKHOUT, BERNARD ADRI
To: STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK
Reel/Frame 019669/0750 →
Priority Claims (1)
EP 97200730 · Mar 11, 1997 · regional
Continuity (3)
Continuation 1038247900 · Mar 6, 2003
Continuation 0938112200
Related Publication 20080138358A1 · Jun 12, 2008